This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

Oral tobacco use, also known as moist snuff, is associated with slower progression of multiple sclerosis (MS), a new study shows. "Our finding that snuff use is not associated with worse disease ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

A genome-wide association study (GWAS) including more than 22,000 people with multiple sclerosis (MS) has uncovered the first genetic variant associated with faster progression of the autoimmune ...

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before disability worsened between people taking certain medications and those not ...

Please provide your email address to receive an email when new articles are posted on . Researchers added a treatment arm to an ongoing study of nine patients with MS who were given clemastine ...

A cross-sectional, prospective study found that gray matter atrophy was more prevalent in patients with more severe progressive multiple sclerosis (MS) compared with those with less severe progressive ...

Endothelial cell dysfunction may contribute to the progress of multiple sclerosis (MS) but directly measuring the extent of damage to this layer of cells has been difficult. In May Neurology, Alireza ...

The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.